Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2012
03/28/2012CN102395371A 5-ht4 receptor agonist compounds for treatment of cognitive disorders
03/28/2012CN102395365A Combination of avermectins or mylbemycins with adrenergic receptors for treating or preventing skin diseases
03/28/2012CN102395364A Pharmaceutical compositions
03/28/2012CN102391517A Nanometer micelle capable of intelligently releasing medicine as well as preparation method and application thereof
03/28/2012CN102391222A Novel hydroxamates as therapeutic agents
03/28/2012CN102389572A Chitosan-carboxylated chitosan nanosphere loading insoluble antitumor drug and preparation method and application thereof
03/28/2012CN102389569A Application of ErbB receptor agonist in preparing medicines for treating ischemic cerebrovascular diseases
03/28/2012CN102389512A Application of extracts of Chinese herbal medicine aloe in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity
03/28/2012CN102389458A Application of Chinese herbal medicine Radix Salviae Miltiorrhizae extract for preparing anti-obesity and antihyperlipidemic drugs or drugs with lipase activity inhibitory effect
03/28/2012CN102389453A Application of Chinese herbal medicine honeysuckle extract for preparing anti-obesity and antihyperlipidemic drugs or drugs with lipase activity inhibitory effect
03/28/2012CN102389444A Application of extracts of Chinese herbal medicine jasmine in preparation of weight-losing and lipid-lowering medicines or medicines with function of inhibiting lipase activity
03/28/2012CN101744809B Combined drug of anethole and fenofibrate drugs
03/27/2012US8143267 Dosing interval of the nimesulide overlaps with that of the oxycodone to reduce the amount of oxycodone needed to provide an effect
03/27/2012US8143005 Nucleic acids encoding sodium channel SCN1A alpha subunit proteins and mutations associated with epilepsy
03/27/2012US8142810 Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
03/27/2012US8142798 Augmentation of titer for vaccination in animals
03/27/2012US8142773 Isolating progenitor cell tissue via antibody specific binding, transfering into recipient host, monitor cell propagation; tissue engineering; regenerative medicine
03/27/2012US8142772 Attack of tumor cells with missing, low or aberrant MHC expression by combining non MHC-restricted T-cells/NK-cells and MHC-restricted cells
03/27/2012US8142763 Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining
03/27/2012CA2667068C 2-pyridinecarboxamide derivative having gk-activating effect
03/27/2012CA2603671C Insp163 polypeptides for the treatment or prevention of cancer and arthritis
03/27/2012CA2538750C Method for configuring air-core photonic-bandgap fibers free of surface modes
03/27/2012CA2532347C Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
03/27/2012CA2529007C Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases
03/27/2012CA2513427C Compounds having anti-proliferative properties
03/27/2012CA2473669C Use and preparation of dosage forms containing benzimidazole derivatives and a buffer
03/27/2012CA2470245C Ifnar2 mutants, their production and use
03/27/2012CA2454699C Method for treating primary insomnia
03/27/2012CA2435812C Process and compositions for peptide, protein and peptidomimetic synthesis
03/27/2012CA2407423C Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
03/27/2012CA2389570C Methods for treating mild cognitive impairment
03/22/2012WO2012037239A1 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
03/22/2012WO2012037072A1 Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
03/22/2012WO2012036287A1 Novel cortistatin a analog and use thereof
03/22/2012WO2012036214A1 Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
03/22/2012WO2012036193A1 Therapeutic agent for fatty liver disease containing p2x7 receptor inhibitory substance as active ingredient
03/22/2012WO2012036168A1 Composition for treating muscular dystrophy
03/22/2012WO2012035131A1 Treatment of abl overexpressing b-cell lymphoma
03/22/2012WO2011141929A3 Aqueous pharmaceutical compositions of fluticasone and olopatadine
03/22/2012WO2011132114A3 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment
03/22/2012US20120071657 Triazole compounds useful as protein kinase inhibitors
03/22/2012US20120071537 New Oral Formulation
03/22/2012US20120071470 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
03/22/2012US20120071454 Steroid Compounds and Treatment Methods
03/22/2012US20120071452 Combinations comprising antimuscarinic agents and corticosteriods
03/22/2012US20120070501 Method and Formulation for Treating Resistance to Antihypertensives and Related Conditions
03/22/2012US20120070384 Topical antifungal composition
03/22/2012CA2811285A1 Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
03/22/2012CA2810254A1 Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients
03/21/2012EP2431480A2 Methods and compositions for increasing the stress resistance of cells and organisms
03/21/2012EP2431393A1 Anti-axl antibody
03/21/2012EP2431385A2 Combination therapy with chlorotoxin
03/21/2012EP2431046A1 Use of olive leaf extracts in a pharmaceutical composition for inducing angiogenesis and vasculogenesis
03/21/2012EP2431037A1 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
03/21/2012EP2430923A1 Compositions and methods for liver growth and liver protection
03/21/2012EP2429585A1 Vaccine immunotherapy
03/21/2012EP2429568A1 Macrocyclic compounds as hepatitis c virus inhibitors
03/21/2012EP2429559A1 Treatment of pain and/or inflammation and treatment and prevention of a skin or mucosal disease and/or condition
03/21/2012EP2429558A1 Medicine for dental diseases prophylaxis
03/21/2012EP2429518A1 Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
03/21/2012EP2429516A2 Combination of a pbospboinositkle 3-ks ase inhibitor and an antidiabetic compound
03/21/2012EP2429515A1 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
03/21/2012EP2429509A1 Lycopene and resveratrol compositions for nk cell activation resulting in anti-neoplastic effect
03/21/2012EP2429507A2 Phosphate-free pharmaceutical composition for the treatment of glaucoma
03/21/2012EP2429299A1 Treating male infertility secondary to sperm oxidative stress
03/21/2012EP1506409B1 Assays for modulators of asparaginyl hydroxylase
03/21/2012EP1488808B1 Remedies for glomerular diseases
03/21/2012EP1478399B1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
03/21/2012EP1436624B1 A method of diagnosis and treatment and agents useful for same
03/21/2012EP1387854B1 Sfrp and peptide motifs that interact with sfrp and methods of their use
03/21/2012EP1320540B9 Peptidomimetic protease inhibitors
03/21/2012EP1313853B1 Modulation of fas and fasl expression by a synthetic phosphodiester oligonucleotide and an anti-fas antibody
03/21/2012EP1289533B1 Whitening compositions containing ascomycete derived enzyme
03/21/2012EP1158872B1 Dietary compositions and methods
03/21/2012CN102388139A Modulation of toll-like receptor 5 expression by antisense oligonucleotides
03/21/2012CN102387805A Use of ribose in first response to acute myocardial infarction
03/21/2012CN102387796A Satiety-inducing composition
03/21/2012CN102387795A Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
03/21/2012CN102380101A Pholcodine-containing compound pharmaceutical preparation for treating cold
03/21/2012CN102380100A Stable protease composition
03/21/2012CN102380099A Application of Wnt2 to preparation of medicament for inhibiting esophageal cancer
03/21/2012CN102380098A Combination therapy for the treatment of ocular neovascular disorders
03/21/2012CN102379896A Medicine composite for dehydrating, shrinking and eliminating lesion tissues
03/21/2012CN102379874A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
03/21/2012CN101979090B Medicament for treating tumors
03/21/2012CN101721706B Medicine composition containing matrine class alkaloid, preparation method and pharmaceutical application
03/21/2012CN101628905B C-aryl glucoside sglt2 inhibitors and method
03/21/2012CN101559227B Pharmaceutical compositions and their use for manufacturing the medicament for treating atherosclerosis, dyslipidemias and related conditions
03/21/2012CN101555283B Antibodies to non-functional p2x7 receptor, diagnosis and treatment of cancers and other conditions
03/21/2012CN101553216B Treatment of inflammatory diseases
03/21/2012CN101496814B Application of mesenchymal stem cell in preparing medicament for inhibiting chronic rejection after blood vessel transplantation
03/21/2012CN101426488B Stable oral pharmaceutical composition containing thyroid hormone receptor agonists
03/21/2012CN101007803B Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
03/20/2012US8138158 Compositions and methods for therapy for diseases characterized by defective chloride transport
03/20/2012US8138154 Biglycan and related therapeutics and methods of use
03/20/2012US8138147 Conditioned cell culture medium compositions and methods of use
03/20/2012US8138141 HMG1 antibody for treating inflammatory conditions
03/20/2012US8137696 Biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan
03/20/2012US8137682 Fibronectins; inflammation
03/20/2012US8137662 Proliferated cell lines and uses thereof
1 ... 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 ... 1151